Efficacy, safety and population pharmacokinetics of artesunate-mefloquine combination for the treatment of uncomplicated falciparum malaria in African children versus artemether-lumefantrine: an open label prospective randomised controlled clinical trial

Drugs for Neglected Diseases initiative (DNDi) (Switzerland)0 个研究点目标入组 940 人开始时间: 2010年8月26日最近更新: 2017年4月24日

适应症

试验速览

暂无简介。

•1. Aged between 6 to 59 months, either sex
•2. Presence of acute uncomplicated P. falciparum mono-infection confirmed by:
•2.1. Axillary temperature greater than 37.5°C, and
•2.2. Positive microscopy of P. falciparum with parasite density between 2,000 and 200,000 asexual parasites/µl
•3. Written informed consent from parent/guardian

•1. Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000
•2. Weight less than 5 kg
•3. Inability to tolerate oral medication (presence of any of the following danger signs: unable to drink or breastfeed, severe vomiting, recent history of convulsions, lethargic or unconscious state, unable to sit or stand up)
•4. Mixed Plasmodium infection
•5. Presence of febrile conditions caused by diseases other than malaria
•6. Known history of hypersensitivity, allergic or serious adverse reactions to mefloquine, quinine, quinidine, artesunate or other artemisinins
•7. History of use of any anti-malarial agent within 2 weeks prior to start of the study (except mefloquine and piperaquine within 4 weeks)
•8. Prior participation in a therapeutic trial within 3 months

发起方

Drugs for Neglected Diseases initiative (DNDi) (Switzerland)